Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s ...
With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy ...
United Community Banks, Inc. (NYSE:UCB) Q3 2024 Earnings Call Transcript October 23, 2024 Operator: Good morning and welcome to United Community Bank's Third Quarter 2024 Earnings Call. Hosting the ...
UCB recently hosted the orientation programme for this year’s third intake of the Monash College Diploma programme.
Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to ...
UCB today announced that the company has regained all global rights to bepranemab following termination of a collaboration ...